Concepedia

Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors

Shigemitsu Matsumoto, Naoki Miyamoto, Takaharu Hirayama, Hideyuki Oki, Kengo Okada, Michiko Tawada, Hidehisa Iwata, Kazuhide Nakamura, Seiji Yamasaki, Hiroshi Miki,

Bioorganic & Medicinal Chemistry · 2013 · 56 citations · 25 references

DOIFull text

Open access

Concepts

References

25

Transplacental Carcinogenesis by Stilbestrol

Judah Folkman · New England Journal of Medicine · 1971 · 2.6K citations

, , +17

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

Brian I. Rini, Bernard Escudier, Piotr Tomczak et al. · The Lancet · 2011 · 1.8K citations

, , +8

Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

Robert J. Motzer, M. Dror Michaelson, Bruce G. Redman et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text

, , +17

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text

, , +17

Discovery of 5-[[4-[(2,3-Dimethyl-2<i>H</i>-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor

Philip A. Harris, Amogh Boloor, Mui Cheung et al. · Journal of Medicinal Chemistry · 2008 · 345 citations · Full text

, , +15